Charming Medical Limited Announces Nasdaq Delisting Determination and Suspension of Trading
Any over-the-counter trading may face limited information, reduced liquidity and greater volatility.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Charming Medical (Nasdaq: MCTA) announced that trading in its securities will be suspended at the opening of business on November 9, 2026.
The company did not request a hearing by the November 5, 2026 deadline following Nasdaq’s delisting determination dated October 29, 2026. Trading has remained halted since November 26, 2025. Nasdaq will subsequently file Form 25-NSE to remove the securities from Nasdaq listing and registration. The determination has no immediate effect on ongoing operations or financial condition. The securities may be eligible for over-the-counter quotation after suspension, but a trading market is not assured.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- None.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Nasdaq trading suspension begins November 9, 2026, after the company missed the November 5 hearing-request deadline.
- Minor point. Forward-looking: it has not happened yet and may not happen.Nasdaq’s delisting determination will be followed by Form 25-NSE removing the securities from Nasdaq listing and registration.
- Minor point. Forward-looking: it has not happened yet and may not happen.Over-the-counter quotation is uncertain; any trading may face limited information, reduced liquidity and greater volatility.
News Explained
Nasdaq’s stated basis is its rule permitting delisting where potential third-party misconduct follows an SEC trading suspension; the company says Nasdaq has communicated no finding that Charming Medical engaged in wrongdoing.
Key Figures
- Hearing request deadline
- November 5, 2026
- The company did not request a hearing by this deadline
- Nasdaq trading suspension
- November 9, 2026
- Suspension scheduled for the opening of business
- SEC trading suspension
- November 12–25, 2025
- Temporary suspension cited in the delisting-rule context
- Nasdaq trading halt
- November 26, 2025
- The halt has remained in effect since this date
Key Terms
form 25-nse regulatory
otc financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Hong Kong, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Charming Medical Limited (Nasdaq: MCTA) (the “Company”), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced that, because the Company did not request a hearing by the November 5, 2026 deadline, trading in the Company’s securities on The Nasdaq Stock Market LLC (“Nasdaq”) will be suspended at the opening of business on November 9, 2026.
As previously announced on November 5, 2026, the Company received a delisting determination letter, dated October 29, 2026, from the Listing Qualifications Staff of Nasdaq notifying the Company that Nasdaq Staff has determined to delist the Company’s securities from Nasdaq pursuant to Nasdaq Listing Rule IM-5101-4.
The U.S. Securities and Exchange Commission (the “SEC”) temporarily suspended trading in the Company’s securities from November 12, 2025 through November 25, 2025 because of potential manipulation in the securities of the Company effectuated through recommendations made to investors by unknown persons via social media to purchase, hold, and/or sell the securities of the Company and to send screenshots documenting their transaction, which appear to be designed to artificially inflate the price and trading volume of the securities of the Company (the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104176-ts.pdf). On November 26, 2025, Nasdaq halted trading in the Company’s securities, and the halt has remained in effect since then.
Nasdaq Listing Rule 5101 provides Nasdaq with “broad discretionary authority over the initial and continued listing of securities in Nasdaq in order to maintain the quality of and public confidence in its market, to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, and to protect investors and the public interest.” Listing Rule IM-5101-4 further expands on this authority, allowing Nasdaq “to exercise discretion to delist a company from Nasdaq based on the potential for one or more third parties to engage in misconduct impacting a company’s securities where the SEC has implemented a temporary trading suspension.”
Nasdaq will subsequently file a Form 25-NSE with the SEC, which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. The Company will make further announcements as and when appropriate.
To date, Nasdaq has not communicated any findings or determination that the Company engaged in wrongdoing in connection with the recent trading activity in the Company’s securities or otherwise. The delisting determination does not have any immediate effect on the Company’s ongoing business operations or financial condition, and the Company will continue to conduct its business in the ordinary course.
Following the suspension of trading on Nasdaq, the Company’s securities may be eligible for quotation in the over-the-counter (OTC) market. However, there can be no assurance that any broker-dealer will make a market in or quote the Company’s securities or that an active or sustained secondary trading market will develop for the Company’s securities. Trading in the over-the-counter market may be subject to limited availability of information, reduced liquidity and greater volatility.
About Charming Medical Limited
Charming Medical Limited (the “Company”) is a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. The Company integrates TCM principles with modern technology to enhance quality of life and promote holistic well-being. Through its four wellness centers in Hong Kong, the Company offers a wide range of services, including womb-warming therapy, pelvic detox therapy, moxibustion, prenatal massage, and traditional abdominal binding, designed to address women’s health issues such as menstrual irregularities, hormonal imbalance, and postpartum recovery. Under its “Beauty Lab” brand, Charming Medical Limited also develops and distributes TCM-inspired supplements and beauty products, such as uterine care patches, probiotic washes, and nourishing herbal formulations, aimed at improving women’s constitution and vitality. In addition, the Company provides technical training, dietary therapy consultancy, and franchise opportunities to extend its wellness philosophy to other practitioners and entrepreneurs. For more information, please visit https://charmingmed.com.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement and Form 20-F filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
Investor Relations Contacts
Charming Medical Limited
Investor Relations
Tel: +852-3797-8461
Email: ir@hkbeautylab.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Charming Medical (MCTA) trading be suspended on Nasdaq?
Trading will be suspended at the opening of business on November 9, 2026. Charming Medical did not request a hearing by the November 5, 2026 deadline. Its securities have already been subject to a Nasdaq trading halt since November 26, 2025.